Air Industries Group (AIRI) - Q2 2024 Filing Summary
Business Context and Reporting Period
Air Industries Group (AIRI) is a manufacturer of precision components and assemblies for aerospace and defense contractors, with end-users including the U.S. Government and commercial airlines. This Form 10-Q covers the quarterly period ended June 30, 2024. The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Net Sales | $13,572,000 | $27,633,000 | - |
| Gross Profit | $2,644,000 (19.5% margin) | $4,550,000 (16.5% margin) | - |
| Net Income (Loss) | $298,000 | $(408,000) | - |
| Operating Cash Flow | - | $334,000 | - |
| Total Debt | - | - | $24,939,000 |
| Cash & Equivalents | - | - | $247,000 |
| Working Capital | - | - | $11,791,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.8% in Q2 2024 and 7.3% YTD compared to 2023, driven by shifts in product mix and increased demand for specific platforms (e.g., E2-D Hawkeye, GTF engines).
- Profitability Improvement: The company returned to profitability in Q2 2024 with a net income of $298,000, compared to a net loss of $395,000 in Q2 2023. Gross margin expanded to 19.5% in Q2 from 16.4% in the prior year.
- Customer Concentration Shift: Northrop Grumman's share of sales surged to 30.5% in Q2 2024 from 3.9% in Q2 2023, while RTX's share decreased to 22.4% from 36.3%.
- Debt Increase: Total debt rose to $24.9 million from $23.3 million at year-end 2023, primarily due to increased borrowings under the Current Credit Facility and the Solar Credit Facility.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has disclosed substantial doubt about the company's ability to continue as a going concern for the next 12 months. This is due to the risk of failing to meet financial covenants under the Current Credit Facility, which could lead to interest rate hikes or a cessation of lending.
- Covenant Compliance: The company recently secured a Seventh Amendment to its credit facility (May 31, 2024) waiving a previous default. It met the EBITDA requirement for the six months ended June 30, 2024 ($1.775M actual vs. $740k required).
- Backlog: Backlog increased to $100.7 million as of June 30, 2024, up from $98.1 million at year-end 2023. Total unfilled contract value is estimated at $174.8 million including potential LTA orders.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting related to IT systems, which remains unremediated as of June 30, 2024.
- Litigation: An ongoing dispute with Contract Pharmacal Corp. regarding a sublease remains in the appellate stage, with the company contesting claims of up to $700,000.
Investor Verification Checklist
- Covenant Adherence: Verify the company's ability to meet the Fixed Charge Coverage Ratio and EBITDA covenants for the quarters ending September 30 and December 31, 2024.
- Liquidity Runway: Assess the sufficiency of the $8.85 million remaining availability on the revolving credit line against upcoming debt service obligations.
- Customer Concentration: Monitor the sustainability of the increased revenue reliance on Northrop Grumman (30.5% of Q2 sales).
- Capital Expenditures: Review the impact of planned $750,000 in additional capital equipment investments on cash flow for the remainder of 2024.
- Remediation of Controls: Track progress on remediation of the material weakness in IT internal controls.